| | english | español | français |
Go to record ID

  Home|Finding Information|Record details   Printer-friendly version

Second Regular National Report on the Implementation of the Cartagena Protocol on Biosafety
Record information and status
Record ID
102642
Status
Published
Date of creation
2011-10-31 14:48 UTC (andrew.bowers@cbd.int)
Date of last update
2011-11-11 16:27 UTC (andrew.bowers@cbd.int)
Date of publication
2011-11-11 16:27 UTC (andrew.bowers@cbd.int)

This document is also available in the following languages:
Origin of report
Country
  • Guatemala
Contact officer for report
Coordinates
Lic. Edgar Selvin Pérez Pérez
Punto Focal BCH
Consejo Nacional de Areas Protegidas
5ª. Avenida 6-06, Zona 1, Edif. IPM 6to. Nivel
Guatemala
Guatemala
Phone:+502-24226700 exts 3003, 2003, 2000
Fax:+502-2253-4141
Email:otecbio@conap.gob.gt,chijunil@yahoo.com
Consulted stakeholders
9. Organizations/stakeholders who were consulted or participated in the preparation of this report
ES
Consejo Nacional de Areas Protegidas (Depto Vida Silvestre, OTECBIO, Depto Juridico), Ministerio de Ambiente y de Recursos Naturales, Ministerio de Agricultura, Ganadería y Alimentación, Ministerio de Salud Pública y Asistencia Social, Instituto de Ciencia y Tecnología Agrícolas, Comisión Nacional de Ciencia y Tecnología, Asociación de Azucareros de Guatemala, OIRSA, Facultad de Agronomía Universidad de San Carlos de Guatemala,                    Gremial de Fabricantes de Alimentos, CENGICAÑA.
Submission
10. Date of submission
2011-10-31
11. Time period covered by this report
Start date
2005-12-08
Time period covered by this report
End date
2011-10
Party to the Cartagena Protocol on Biosafety
12. Is your country a Party to the Cartagena Protocol on Biosafety (CPB)?
  • Yes
Article 2 – General provisions
15. Has your country introduced the necessary legal, administrative and other measures for the implementation of the Protocol?
  • Only a draft framework exists
16. Which specific instruments are in place for the implementation of your national biosafety framework?
  • One or more national biosafety regulations
17. Has your country established a mechanism for the budgetary allocations of funds for the operation of its national biosafety framework?
  • No
18. Does your country have permanent staff to administer functions directly related to the national biosafety framework?
  • No
20. Has your country’s biosafety framework / laws / regulations / guidelines been submitted to the Biosafety Clearing-House (BCH)?
  • Partially
21. Here you may provide further details on the implementation of Article 2 in your country:
ES
Guatemala no cuenta con un Marco Jurídico aprobado, pero existe la propuesta de Ley de Seguridad de la Biotecnología Moderna para Guatemala, elaborada en el año 2004 como parte del Proyecto GUA/02/G21 "Desarrollo del Marco Nacional de Seguridad de la Biotecnología para Guatemala (2002-2004)", ejecutado por el Consejo Nacional de Áreas Protegidas -CONAP-, y financiado por el Fondo Mundial para el Medio Ambiente (GEF) y el Programa de Naciones Unidas para el Medio Ambiente (PNUMA). El producto principal de este Proyecto fue la propuesta de Ley de Seguridad de la Biotecnología Moderna para Guatemala, la cual fue presentada ante la Comisión de Ambiente y de Recursos Naturales del Congreso de la Republica de Guatemala. Actualmente se encuentra en Segunda Lectura.

Se considera como Marco Juridico vigente el Acuerdo Ministerial 386-2006 (modificado del AM 393-98) del Ministerio de Agricultura, Ganadería y Alimentación, el cual  establece los requisitos para la importación, transporte, manejo dentro del país, establecimiento de experimentos de campo y producción para exportación de OVM´s de uso agricola (solo semillas), no para consumo humano, por lo cual no permite la comercialización interna de las variedades de OVM´s.  Este es un  Acuerdo de observancia general en la república de Guatemala, aplicable a las personas individuales y/o jurídicas interesadas en efectuar pruebas experimentales, producir y exportar semillas de OVM´s.

En terminos generales, en el Pais existen disposiciones que se aplican de manera directa e indirecta a la protección del medio ambiente, la biodiversidad y la salud humana. Entre las que se incluyen la Constitución Politica de Guatemala, Decreto 68-86 del Congreso de la Republica, Ley de Protección y Mejoramiento del Medio Ambiente, y sus reformas; el Reglamento de Evaluación y Control y Seguimiento Ambiental, y la Ley de Sanidad Vegetal y Animal (Decreto 36-98 del Congreso de la República), entre otras. 

A partir del 2011 Guatemala inició la elaboración de la Politica Nacional de Seguridad en el Uso de la Biotecnología Moderna, la cual está en proceso de consulta con los sectores,  gubernamentales, academico, la iniciativa privada y la sociedad civil.

Respecto al personal, no hay personal permanente asignado para el Marco Regulatorio. Con el actual proyecto "Desarrollo e implementación del Protocolo de Cartagena" existe el Comité Nacional de Apoyo a la elaboración de la Política, el cual es visualizado como un ente ad honorem, multi-sectorial con carácter de asesor y orientador técnico en materia de  Seguridad de la Biotecnología, que ejerce el mandato de promoción y proposición de instrumentos de política y legales en materia de su competencia. Dentro de este Proyecto se  cuenta con un Comité Directivo, el cual está conformado por:

1. Un titular y suplente del Ministerio de Ambiente y  Recursos Naturales
2. Un titular y suplente del Ministerio de Agricultura, Ganadería y Alimentacion.
3. Un titular y suplente del Ministerio de Economía
4. Un titular y suplente del Ministerio de Salud Publica y Asistencia Social
5. Un titular y suplente de la Comisión de Ciencia y Tecnología
6. Un titular y suplente del Consejo Nacional de Areas Protegidas. 
Article 5 – Pharmaceuticals
22. Does your country regulate the transboundary movement, handling and use of living modified organisms (LMOs) which are pharmaceuticals?
  • Yes, to some extent
23. If you answered Yes to question 22, has this information been submitted to the BCH?
  • Not applicable
24. Here you may provide further details on the implementation of Article 5 in your country:
ES
El Código de salud Decreto 90-97 establece establece en su capítulo III "De los Productos Farmaceúticos y Otros afines" 4 secciones que define lo que es el producto farmaceútico, registro autorizaciones, vigilancia sin hacer alusión a la Biotecnología moderna ni a pasos transfronterizos, sí se menciona responsabilidad de calidad y Certificación Sanitaria y se establece en el Art. 175 que de los acuerdos internacionales suscritos por Guatemala en temas de medicamentos contemplarán aspectos de legislación, fortalecimiento, seguridad, calidad y eficacia de los mismos y un trato recíproco para los productos guatemaltecos, productos importados a través de procedimientos armonizados y aprobados por el Ministerio de Salud.
Article 6 – Transit and Contained use
25. Does your country regulate the transit of LMOs?
  • No
26. Does your country regulate the contained use of LMOs?
  • No
28. Here you may provide further details on the implementation of Article 6 in your country:
ES
La iniciativa de Ley de Seguridad de la Biotecnología Moderna para Guatemala  si contempla la regulación de OVM´s en transito y de uso confinado, pero siendo un Proyecto en Segunda Lectura del Congreso aun no es aplicable.

El Acuerdo Ministerial 386-2006 para el tratamiento de semillas no hace diferencia en cuanto al tratamiento de los organismos.
Articles 7 to 10 – Advance Informed Agreement (AIA) and intentional introduction of LMOs into the environment
29. Has your country adopted law(s) / regulations / administrative measures for the operation of the AIA procedure of the Protocol?
  • No
30. Has your country adopted a domestic regulatory framework consistent with the Protocol regarding the transboundary movement of LMOs for intentional introduction into the environment?
  • No
31. Has your country established a mechanism for taking decisions regarding first intentional transboundary movements of LMOs for intentional introduction into the environment?
  • No
33. Has your country established a mechanism for monitoring potential effects of LMOs that are released into the environment?
  • No
34. Does your country have the capacity to detect and identify LMOs?
  • No
35. Has your country established legal requirements for exporters under its jurisdiction to notify in writing the competent national authority of the Party of import prior to the intentional transboundary movement of an LMO that falls within the scope of the AIA procedure?
  • No
36. Has your country established legal requirements for the accuracy of information contained in the notification?
  • No
37. Has your country ever received an application / notification regarding intentional transboundary movements of LMOs for intentional introduction into the environment?
  • No
38. Has your country ever taken a decision on an application / notification regarding intentional transboundary movements of LMOs for intentional introduction into the environment?
  • Not applicable
39. If you answered Yes to question 38, how many LMOs has your country approved to date for import for intentional introduction into the environment?
  • Not applicable
40. If you answered Yes to question 38, how many LMOs, not imported, has your country approved to date for intentional introduction into the environment?
  • Not applicable
41. In the current reporting period, how many applications/notifications has your country received regarding intentional transboundary movements of LMOs for intentional introduction into the environment?
  • None
42. In the current reporting period, how many decisions has your country taken regarding intentional transboundary movements of LMOs for intentional introduction into the environment?
  • None
50. Here you may provide further details on the implementation of Articles 7-10 in your country, including measures in case of lack of scientific certainty on potential adverse effects of LMOs for intentional introduction to the environment:
ES
No se ha aplicado el Acuerdo Fundamentado Previo por no haber ingresado ninguna solicitud. Sin embargo, en el 2006, el Ministerio de Agricultura, Ganadería y Alimentación (MAGA)  recibió solicitudes para investigación de OVM´s en el cultivo de maiz, pero no llegaron a campo debido a que no cumplian con los requesitos solicitados en la normativa del Ministerio de Ambiente

En Guatemala existe algun tipo de capacidad instalada pero no se cuenta con el rigor y confiabilidad requerido para detectar OVM´s. Actualmente, en el país existen laboratorios de biotecnología que están trabajando principalmente en aspectos relativos  a agricultura, ambiente y salud, pero en su amplia mayoría estos desarrollan técnicas biotecnológicas no relacionadas con la creación y manejo de OVM's. Entre las instituciones que tienen cierta capacidad se encuentran: el Ministerio de Agricultura, Ganadería de Alimentación, Universidad del Valle de Guatemala, el Instituto de Ciencia y Tecnología Agricolas, el Laboratorio Nacional de Salud, y algunas empresas privadas, entre otros. Se considera que existen unas 18 instituciones que cuentan con laboratorios de Biotecnología en Guatemala en el área vegetal, animal y humana.
Article 11 – Procedure for living modified organisms intended for direct use as food or feed, or for processing (LMOs-FFP)
51. Has your country adopted specific law(s) or regulation(s) for decision-making regarding domestic use, including placing on the market, of LMOs-FFP?
  • No
52. Has your country established legal requirements for the accuracy of information to be provided by the applicant?
  • No
53. Has your country established a mechanism to ensure that decisions regarding LMOs-FFP that may be subject to transboundary movement will be communicated to the Parties through the BCH?
  • No
54. Has your country established a mechanism for taking decisions on the import of LMOs-FFP?
  • No
55. Has your country declared through the BCH that in the absence of a regulatory framework its decisions prior to the first import of an LMO-FFP will be taken according to Article 11.6 of the Cartagena Protocol on Biosafety?
  • No
56. Has your country indicated its needs for financial and technical assistance and capacity building in respect of LMOs-FFP?
  • No
57. Has your country ever taken a decision on LMOs-FFP (either on import or domestic use)?
  • No
63. Here you may provide further details on the implementation of Article 11 in your country, including measures in case of lack of scientific certainty on potential adverse effects of LMOs-FFP:
ES
Guatemala como pais no ha adoptado una decisión definitiva relacionado con OVM-AHAP, por lo que tampoco lo ha comunicado al CIISB.

Sin embargo, el CONAP ha desarrollado el mecanismo del Biosafety Clearing House Mechanism, el cual será utilizado cuando se haya tomado una decisión definitiva con respecto a OVM-AHAP.
Article 12 – Review of decision
64. Has your country established a mechanism for the review and change of a decision regarding an intentional transboundary movement of LMOs?
  • No
65. Has your country ever received a request for a review of a decision?
  • No
66. Has your country ever reviewed / changed a decision regarding an intentional transboundary movement of LMOs?
  • No
67. In the current reporting period, how many decisions were reviewed and/or changed regarding an intentional transboundary movement of an LMO?
  • None
Article 13 – Simplified procedure
72. Has your country established a system for the application of the simplified procedure regarding an intentional transboundary movement of LMOs?
  • No
73. Has your country ever applied the simplified procedure?
  • No
75. In the current reporting period, how many LMOs has your country applied the simplified procedure to?
  • None
Article 14 – Bilateral, regional and multilateral agreements and arrangements
77. Has your country entered into any bilateral, regional or multilateral agreements or arrangements?
  • No
Article 15 – Risk assessment
81. Has your country established a mechanism for conducting risk assessments prior to taking decisions regarding LMOs?
  • No
83. Has your country established guidelines for how to conduct risk assessments prior to taking decisions regarding LMOs?
  • No
84. Has your country acquired the necessary domestic capacity to conduct risk assessment?
  • No
85. Has your country established a mechanism for training national experts to conduct risk assessments?
  • No
86. Has your country ever conducted a risk assessment of an LMO for intentional introduction into the environment?
  • No
87. Has your country ever conducted a risk assessment of an LMO intended for direct use as food or feed, or for processing?
  • No
88. If your country has taken decision(s) on LMOs for intentional introduction into the environment or on domestic use of LMOs-FFP, were risk assessments conducted for all decisions taken?
  • No
89. Has your country submitted summary reports of the risk assessments to the BCH?
  • Not applicable
90. In the current reporting period, if your country has taken decisions regarding LMOs, how many risk assessments were conducted in the context of these decisions?
  • None
91. Has your country ever required the exporter to conduct the risk assessment(s)?
  • Not applicable
92. Has your country ever required the notifier to bear the cost of the risk assessment(s) of LMOs?
  • Not applicable
93. Here you may provide further details on the implementation of Article 15 in your country:
ES
En general capacitación, Guatemala no cuenta con un mecanismo para formación de expertos en Evaluaciones de Riesgo, pero si ha desarrollado varios talleres para capacitar a tecnicos nacionales. En el 2011, con el apoyo del Proyecto "Desarrollo de Mecanismos para la Implementación del Protocolo de Cartagena en Guatemala", se efectuo 4 talleres de entrenamiento en Bioseguridad, BCH, y Biotecnología. Así también se ha participado en conferencias y talleres internacionales.

El CONAP en coordinación con la Facultad de Agronomia de la Universidad de San Carlos de Guatemala ha iniciado un Diplomado en Biotecnología y Bioseguridad, con el fin de capacitar profesionales guatemaltecos del sector agropecuario, salud, academico e industrial, en temas de actualidad sobre la biotecnología y bioseguridad.

En un esfuerzo adicional, el Ministerio de Agricultura, Ganadería y Alimentación, en colaboración con la SENACYT y otras insituciones coordinaron el Taller "Evaluación y Gestión de Riesgo en la Biotecnología Moderna" (Abril 2011), en el cual se capacitó 46 técnicos de 26 instituciones a nivel nacional.
                                         
Respecto a las evaluaciones de riesgo, las solicitudes que el MAGA ha recibido han sido  unicamente para experimentación, pero no han sido aprobadas. Sin embargo, el Acuerdo Ministerial 386-2006, establece en sus Articulos 10 y 11 que el MAGA podrá requerir al solicitante que realicé cualquier evaluación de riesgo, según sea el caso. Las evaluaciones de riesgo corren por cuenta del interesado
Article 16 – Risk management
94. Has your country established and maintained appropriate and operational mechanisms, measures and strategies to regulate, manage and control risks identified in risk assessments for:
94.1) LMOs for intentional introduction into the environment?
  • No
94.2) LMOs intended for direct use as food or feed, or for processing?
  • No
95. Has your country established and maintained appropriate measures to prevent unintentional transboundary movements of LMOs?
  • No
96. Has your country taken measures to ensure that any LMO, whether imported or locally developed, undergoes an appropriate period of observation that is commensurate with its life-cycle or generation time before it is put to its intended use?
  • No
97. Has your country cooperated with other Parties with a view to identifying LMOs or specific traits that may have adverse effects on the conservation and sustainable use of biological diversity?
  • No
98. Has your country cooperated with other Parties with a view to taking measures regarding the treatment of LMOs or specific traits that may have adverse effects on the conservation and sustainable use of biological diversity?
  • No
99. Here you may provide further details on the implementation of Article 16 in your country, including any details regarding risk management strategies, also in case of lack of scientific certainty on potential adverse effects of LMOs:
ES
No ha puesto en marcha ninguna Gestion de Riesgo. Sin embargo, el Acuerdo Ministerial 386-2006, establece en su ARTÍCULO 11, que tanto en las pruebas de investigación como en las áreas de producción se establecerán y mantendrán mecanismos, medidas y estrategias adecuadas para regular, gestionar y controlar los riesgos determinados con arreglo a las disposiciones sobre evaluación del riesgo.

Se impondrán medidas basadas en la evaluación del riesgo en la proporción necesaria para evitar efectos adversos de los organismos vivos modificados en la conservación y la utilización sostenible de la diversidad biológica, teniendo también en cuenta los riesgos para la salud humana.
Article 17 – Unintentional transboundary movements and emergency measures
100. Has your country made available to the BCH the relevant details setting out its point of contact for the purposes of receiving notifications under Article 17?
  • Yes
101. Has your country established a mechanism for addressing emergency measures in case of unintentional transboundary movements of LMOs that are likely to have significant adverse effect on biological diversity?
  • No
102. Has your country implemented emergency measures in response to information about releases that led, or may have led, to unintentional transboundary movements of LMOs?
  • No
103. In the current reporting period, how many times has your country received information concerning occurrences that led, or may have led, to unintentional transboundary movement(s) of one or more LMOs to or from territories under its jurisdiction?
  • Never
107. Here you may provide further details on the implementation of Article 17 in your country:
ES
Guatemala a nombrado al Director de Informatica del CONAP como Punto Focal para recibir notificación de medidas de emergencia.
Article 18 – Handling, transport, packaging and identification
108. Has your country taken measures to require that LMOs that are subject to transboundary movement are handled, packaged and transported under conditions of safety, taking into account relevant international rules and standards?
  • No
109. Has your country taken measures to require that documentation accompanying LMOs-FFP clearly identifies that, in cases where the identity of the LMOs is not known through means such as identity preservation systems, they may contain living modified organisms and are not intended for intentional introduction into the environment, as well as a contact point for further information?
  • No
110. Has your country taken measures to require that documentation accompanying LMOs-FFP clearly identifies that, in cases where the identity of the LMOs is known through means such as identity preservation systems, they contain living modified organisms and are not intended for intentional introduction into the environment, as well as a contact point for further information?
  • No
111. Has your country taken measures to require that documentation accompanying LMOs that are destined for contained use clearly identifies them as living modified organisms and specifies any requirements for the safe handling, storage, transport and use, the contact point for further information, including the name and address of the individual and institution to whom the LMO are consigned?
  • No
112. Has your country taken measures to require that documentation accompanying LMOs that are intended for intentional introduction into the environment of the Party of import, clearly identifies them as living modified organisms; specifies the identity and relevant traits and/or characteristics, any requirements for the safe handling, storage, transport and use, the contact point for further information and, as appropriate, the name and address of the importer and exporter; and contains a declaration that the movement is in conformity with the requirements of this Protocol applicable to the exporter?
  • No
113. Does your country have the capacity to enforce the requirements of identification and documentation of LMOs?
  • No
114. Has your country established procedures for the sampling and detection of LMOs?
  • No
115. Here you may provide further details on the implementation of Article 18 in your country:
ES
Actualmente, es el Organismo Internacional Regional de Sanidad Agropecuaria (OIRSA), que es un Organismo de Protección Fitozoosanitario, quien coopera con el MAGA (para el caso de Guatemala), para inspeccionar en los puestos transfronterizos que todo organismo (no procesado) de origen animal o vegetal cuente con la documentación apropiada de importación, la cual se debe gestionar a través del Ministerio de Agricultura, Ganadería y Alimentación.
Article 19 – Competent National Authorities and National Focal Points
116. Has your country designated one national focal point for the Cartagena Protocol to be responsible for liaison with the Secretariat?
  • Yes
117. Has your country designated one national focal point for the Biosafety Clearing-House to liaise with the Secretariat regarding issues of relevance to the development and implementation of the BCH?
  • Yes
118. Has your country designated one or more competent national authorities, which are responsible for performing the administrative functions required by the Cartagena Protocol on Biosafety and are authorized to act on your country’s behalf with respect to those functions?
  • Yes, one
120. Has your country made available the required information referred in questions 116-119 to the BCH?
  • Yes, some information
122. Has your country established adequate institutional capacity to enable the competent national authority(ies) to perform the administrative functions required by the Cartagena Protocol on Biosafety?
  • No
123. Here you may provide further details on the implementation of Article 19 in your country:
ES
En el actual periodo de notificación es el Consejo Nacional de Areas Protegidas, CONAP la institución que aparece como Autoridad Nacional Competente, que a partir del 2004 ha impulsado la implementación del Protocolo en Guatemala. Al periodo de notificación no se ha oficializado el nombramiento de otros Ministerios cuya función se relaciona a la implementación del Protocolo.

El Comité de Apoyo a la elaboración de la Politica Nacional de Bioseguridad, y el Comité Directivo son única la plataforma interinstitucional de Coordinación cuya función es dar seguimiento al proceso de aprobación del Marco Regulatorio Nacional, y la formulación de la Politica Nacional. Este Comité es de carácter temporal y esta conformado por organismos de la iniciativa privada, la academia y los Ministerios de Ambiente y Recursos Naturales,  Ministerio de Agricultura, Ganadería y Alimentación, Ministerio de Salud Publica, y Ministerio de Economia

La información de los Puntos Focales actuales se encuentra ingresada en el CIISB.
Article 20 – Information Sharing and the Biosafety Clearing-House (BCH)
124. Please provide an overview of the status of the information provided by your country to the BCH by specifying for each category of information whether it is available and whether it has been submitted to the BCH.
124.a) Existing national legislation, regulations and guidelines for implementing the Protocol, as well as information required by Parties for the advance informed agreement procedure (Article 20, paragraph 3 (a))
  • Information available but only partially available in the BCH
124.b) National laws, regulations and guidelines applicable to the import of LMOs intended for direct use as food or feed, or for processing (Article 11, paragraph 5)
  • Information not available
124.c) Bilateral, multilateral and regional agreements and arrangements (Articles 14, paragraph 2 and 20, paragraph 3 (b))
  • Information not available
124.d) Contact details for competent national authorities (Article 19, paragraphs 2 and 3), national focal points (Article 19, paragraphs 1 and 3), and emergency contacts (Article 17, paragraph 3 (e))
  • Information available and in the BCH
124.e) Reports submitted by the Parties on the operation of the Protocol (Article 20, paragraph 3 (e))
  • Information available and in the BCH
124.f) Decisions by a Party on regulating the transit of specific living modified organisms (LMOs) (Article 6, paragraph 1)
  • Information not available
124.g) Occurrence of unintentional transboundary movements that are likely to have significant adverse effects on biological diversity (Article 17, paragraph 1)
  • Information not available
124.h) Illegal transboundary movements of LMOs (Article 25, paragraph 3)
  • Information not available
124.i) Final decisions regarding the importation or release of LMOs (i.e. approval or prohibition, any conditions, requests for further information, extensions granted, reasons for decision) (Articles 10, paragraph 3 and 20, paragraph 3(d))
  • Information not available
124.j) Information on the application of domestic regulations to specific imports of LMOs (Article 14, paragraph 4)
  • Information not available
124.k) Final decisions regarding the domestic use of LMOs that may be subject to transboundary movement for direct use as food or feed, or for processing (Article 11, paragraph 1)
  • Information not available
124.l) Final decisions regarding the import of LMOs intended for direct use as food or feed, or for processing that are taken under domestic regulatory frameworks (Article 11, paragraph 4) or in accordance with annex III (Article 11, paragraph 6) (requirement of Article 20, paragraph 3(d))
  • Information not available
124.m) Declarations regarding the framework to be used for LMOs intended for direct use as food or feed, or for processing (Article 11, paragraph 6)
  • Information not available
124.n) Review and change of decisions regarding intentional transboundary movements of LMOs (Article 12, paragraph 1)
  • Information not available
124.o) LMOs granted exemption status by each Party (Article 13, paragraph 1)
  • Information not available
124.p) Cases where intentional transboundary movement may take place at the same time as the movement is notified to the Party of import (Article 13, paragraph 1)
  • Information not available
124.q) Summaries of risk assessments or environmental reviews of LMOs generated by regulatory processes and relevant information regarding products thereof (Article 20, paragraph 3 (c))
  • Information not available
125. Has your country established a mechanism for strengthening the capacity of the BCH National Focal Point to perform its administrative functions?
  • No
126. Has your country established a mechanism for the coordination among the BCH National Focal Point, the Cartagena Protocol focal point, and the competent national authority(ies) for making information available to the BCH?
  • No
127. Does your country use the information available in the BCH in its decision making processes on LMOs?
  • No
128. Has your country experienced difficulties accessing or using the BCH?
  • No
129. If you answered Yes to question 128, has your country reported these problems to the BCH or the Secretariat?
  • Not applicable
130. Is the information submitted by your country to the BCH complete and up-to date?
  • Yes
131. Here you may provide further details on the implementation of Article 20 in your country:
ES
1. Desde Agosto del 2009 el CONAP, a través del Proyecto UNEP/GEF Bioseguridad Clearing House ha diseñado el Biosafety Clearing House Mechanism (BCH) http://www.bchguatemala.gob.gt/, que tiene por objeto divulgar toda la información que aborda la temática de la seguridad de la biotecnología moderna en Guatemala. 

2. La propuesta de Ley para Guatemala, está disponible en el Centro de Intercambio de Información. También está disponible el Acuerdo Ministerial No. 386-2006, Ministerio de Agricultura, Ganadería y Alimentación -MAGA-.

3. Además, Guatemala ha cumplido con ingresar en el CIISB los datos de contacto del Consejo Nacional de Areas Protegidas (CONAP), por medio del cual se designó el Punto Focal.

4. No se han incluido datos de otras autoridades competentes debido a que estas no han sido nombradas oficialmente.

5. Se considera que la información del Pais que se ha puesto en el Central de Información si está actualizada y completa. El portal BCH nacional se encuentra en un proceso de cambio para funcionar bajo la plataforma Hermes, con la finalidad de facilitar la actualización de los registros que se van agregando.

La información actualmente ingresada incluye:

1. Proyecto de Ley de Seguridad de la Biotecnología Moderna para Guatemala

2. Acuerdo Ministerial 386-2006

3. Punto Focal para el Protocolo, Medidas de Emergencia, y para el Centro de Intercambio de Información.

4. Informe Provisional de País, presentado en el año 2005.
Article 21 – Confidential information
132. Has your country established procedures to protect confidential information received under the Protocol?
  • No
133. Does your country allow the notifier to identify information that is to be treated as confidential?
  • No
134. Here you may provide further details on the implementation of Article 21 in your country:
ES
Respecto a este Articulo, aunque no se han recibido solicitudes dentro del Marco del Protocolo, cada institución del País tiene la obligación de mantener la información confidencial de las empresas que remiten solicitudes.
Article 22 – Capacity-building
135. Has your country received external support or benefited from collaborative activities with other Parties in the development and/or strengthening of human resources and institutional capacities in biosafety?
  • Yes
136. If you answered Yes to question 135, how were these resources made available?
  • Multilateral channels
137. Has your country provided support to other Parties in the development and/or strengthening of human resources and institutional capacities in biosafety?
  • No
139. Is your country eligible to receive funding from the Global Environment Facility (GEF)?
  • Yes
140. Has your country ever initiated a process to access GEF funds for building capacity in biosafety?
  • Yes
141. If you answered Yes to question 140, how would you characterize the process?
Please add further details about your experience in accessing GEF funds under question 150.
  • Average
142. Has your country ever received funding from the GEF for building capacity in biosafety?
  • Development of national biosafety frameworks
  • Implementation of national biosafety frameworks
  • Building Capacity for Effective Participation in the BCH (Phase I)
  • Building Capacity for Effective Participation in the BCH (Phase II)
143. During the current reporting period, has your country undertaken activities for the development and/or strengthening of human resources and institutional capacities in biosafety?
  • Yes
144. If you answered Yes to question 143, in which of the following areas were these activities undertaken?
  • Institutional capacity
  • Human resources capacity development and training
  • Risk assessment and other scientific and technical expertise
  • Risk management
  • Information exchange and data management including participation in the Biosafety Clearing-House
  • Scientific, technical and institutional collaboration at subregional, regional and international levels
  • Identification of LMOs, including their detection
145. During the current reporting period, has your country carried out a capacity-building needs assessment?
  • No
146. Does your country still have capacity-building needs?
  • Yes
147. If you answered Yes to question 146, indicate which of the following areas still need capacity-building.
  • Institutional capacity
  • Human resources capacity development and training
  • Risk assessment and other scientific and technical expertise
  • Risk management
  • Public awareness, participation and education in biosafety
  • Information exchange and data management including participation in the Biosafety Clearing-House
  • Scientific, technical and institutional collaboration at subregional, regional and international levels
  • Technology transfer
  • Identification of LMOs, including their detection
  • Socio-economic considerations
  • Implementation of the documentation requirements under Article 18.2 of the Protocol
  • Handling of confidential information
  • Measures to address unintentional and/or illegal transboundary movements of LMOs
  • Scientific biosafety research relating to LMOs
  • Taking into account risks to human health
148. Has your country developed a capacity-building strategy or action plan?
  • No
149. Has your country submitted the details of national biosafety experts to the Roster of Experts in the BCH?
  • No
150. Here you may provide further details on the implementation of Article 22 in your country, including further details about your experience in accessing GEF funds:
ES
1. Guatemala continua fortaleciendo capacidades mediante los Proyectos apoyados por el GEF. El Proyecto Implementación del Protocolo de Cartagena en Guatemala, incluye dentro de sus componentes el fortalecimiento de recurso humano. De esa cuenta en el periodo de notificación se han realizado capacitaciones, cursos y talleres, para fortalecer las capacidades de las instituciones de gobierno relacionadas con la temática. Las bases o fundamentos del Plan de Acción para la Creación de Capacidad Nacional estará incluido como uno de los ejes de la Política Nacional de Seguridad en el Uso de la Biotecnología Moderna.

2. Por su parte, otros organismos gubernamentales, como el MAGA en Convenio con el IICA realizo un taller de capacitación sobre etiquetado y responsabilidad de compensación. En el 2010, se llevo a cabo el Taller sobre el Estado Mundial de los Cultivos Biotecnológicos.  La SENACYT con apoyo de la UNESCO ha elaborado el Subprograma Nacional de Formación de Recursos Humanos en Biotecnología en Guatemala 2010-2022. El CONAP recientemente realizó el intercambio con el CIBIOGEM de Mexico en la implementación del Protocolo de Cartagena en ese país. El Taller tuvo lugar el 5 de Octubre en Guatemala, con la participación de representantes del MAGA, ICTA, CONCYT, Ministerio de Salud Publica, la Superintendencia de Acción Tributaria (SAT), Ministerio de Educación, universidades, y la iniciativa privada, entre otros.

3. Con respecto al FMAM se considera que existe cierto grado de dificultad en la obtención de los fondos, procedimientos y periodos de tramite muy extensos (burocracia y procedimientos engorrosos).
Article 23 – Public awareness and participation
151. Has your country established a strategy or put in place legislation for promoting and facilitating public awareness, education and participation concerning the safe transfer, handling and use of LMOs?
  • No
152. Has your country established a biosafety website?
  • Yes
153. Has your country established a mechanism to ensure public access to information on living modified organisms that may be imported?
  • Yes
154. Has your country established a mechanism to consult the public in the decision-making process regarding LMOs?
  • No
155. Has your country established a mechanism to make available to the public the results of decisions taken on LMOs?
  • Yes
156. Has your country taken any initiative to inform its public about the means of public access to the Biosafety Clearing-House?
  • Yes
157. In the current reporting period, has your country promoted and facilitated public awareness, education and participation concerning the safe transfer, handling and use of LMOs?
  • No
159. In the current reporting period, how many times has your country consulted the public in the decision-making process regarding LMOs and made the results of such decisions available to the public?
  • None
160. Here you may provide further details on the implementation of Article 23 in your country:
ES
No existe un plan de la socialización de la información, ésta se realiza por medio del Portal Nacional sobre Seguridad de la Biotecnología en Guatemala BCH (http://www.bchguatemala.gob.gt). Este funciona como medio de información, aunque se considera que existe poca consultación del público. Además, el CONAP, por medio de los proyectos GEF, ha efectuado talleres, afiches, calendarios, CD´s divulgaticos y manuales en Biotecnolgía y Bioseguridad. En el portal del BCH se ha puesto a disposición del publico documentos y resultados de investigaciones.
Article 24 – Non-Parties
161. Has your country entered into any bilateral, regional, or multilateral agreement with non-Parties regarding transboundary movements of LMOs?
  • No
162. Has your country ever imported LMOs from a non-Party?
  • No
163. Has your country ever exported LMOs to a non-Party?
  • No
166. If your country is not a Party to the Cartagena Protocol, has it contributed information to the BCH on LMOs released in, or moved into, or out of, areas within its national jurisdiction?
  • Not applicable
Article 25 – Illegal transboundary movements
168. Has your country adopted domestic measures aimed at preventing and/or penalizing transboundary movements of LMOs carried out in contravention of its domestic measures to implement this Protocol?
  • Yes
169. Has your country established a strategy for detecting illegal transboundary movements of LMOs?
  • No
170. In the current reporting period, how many times has your country received information concerning cases of illegal transboundary movements of an LMO to or from territories under its jurisdiction?
  • Never
175. Here you may provide further details on the implementation of Article 25 in your country:
ES
Los Códigos Arancelarios actuales no permiten la identificación de OVM´s. El Acuerdo Ministerial 386-2006 establece sanciones para quien ingrese al país materiales geneticamente modificados sin la debida autorizacion; a quien entregue a cualquier titulo materiales sin la identificación correspondiente; y, a quien haga investigación de OVM sin la autorización correspondiente. (Articulo 23).

La iniciativa de Ley en su Articulo 25 contempla todo lo referente a las sanciones que deberán aplicarse.
Article 26 – Socio-economic considerations
176. If your country has taken a decision on import, has it ever taken into account socio-economic considerations arising from the impact of the LMO on the conservation and sustainable use of biological diversity?
  • Not applicable
177. Has your country cooperated with other Parties on research and information exchange on any socio-economic impacts of LMOs?
  • No
Article 27 – Liability and Redress
179. Has your country signed the Nagoya-Kuala Lumpur Supplementary Protocol on Liability and Redress?
  • No
180. Has your country initiated steps towards ratification, acceptance or approval of the Nagoya-Kuala Lumpur Supplementary Protocol?
  • No
Article 33 – Monitoring and reporting
182. Has your country submitted the previous national reports (Interim and First National Reports)?
  • Yes, Interim report only
183. If your country did not submit previous reports, indicate the main challenges that hindered the submission
  • Difficulty in compiling the information from various sectors
Other information
184. Please use this field to provide any other information on issues related to national implementation of the Protocol, including any obstacles or impediments encountered.
ES
Guatemala esta en proceso de formulación de la Politica de OVM´s con la cual se espera operativizar la competencia de las instituciones para la aplicación de este Protocolo. Asi también se requiere de la aprobación y oficilización de la Normativa Nacional, y la asignación de recursos financieros. Además, se requiere instalaciones con tecnología apropiada para realizar los estudios de riesgo, procedimientos para monitorear el movimiento transfronterizo, personal capacitado y capacidad tecnica indispensable para detectar y monitorear los OVM´s. Asimismo, se necesita desarrollar e implementar un mecanismo de comunicación para socializar la información de manera efectiva a todos los niveles de la sociedad.

Re: Q. 14 - Guatemala ratificó el Protocolo de Cartagena en su calidad de Estado Parte firmante, en el mes de agosto del año 2004, según Decreto 44-2003 del Congreso de la Republica de Guatemala.
Comments on reporting format
185. Please use this field to provide any other information on difficulties that you have encountered in filling in this report.
ES
Los espacios para comentar son apropiados para clarificar ciertas preguntas que pudieran tener respuesta ambigua.